An expert panel on the adequacy of safety data and physiological roles of dietary bovine osteopontin in infancy

Stephen A. Fleming; Sarah M. Reyes; Sharon M. Donovan; Olle Hernell; Rulan Jiang; Bo Lönnerdal; Josef Neu; Lawrence Steinman; Esben S. Sørensen; Christina E. West; Ronald Kleinman; John C. Wallingford

doi:10.3389/fnut.2024.1404303

An expert panel on the adequacy of safety data and physiological roles of dietary bovine osteopontin in infancy

Stephen A. Fleming^*, Sarah M. Reyes, Sharon M. Donovan, Olle Hernell, Rulan Jiang, Bo Lönnerdal, Josef Neu, Lawrence Steinman, Esben S. Sørensen, Christina E. West, Ronald Kleinman, John C. Wallingford

^*Corresponding author af dette arbejde

Institut for Molekylærbiologi og Genetik - Cellulær sundhed, intervention og ernæring

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Review › Forskning › peer review

1 Citationer (Scopus)

Abstract

Human milk, due to its unique composition, is the optimal standard for infant nutrition. Osteopontin (OPN) is abundant in human milk but not bovine milk. The addition of bovine milk osteopontin (bmOPN) to formula may replicate OPN’s concentration and function in human milk. To address safety concerns, we convened an expert panel to assess the adequacy of safety data and physiological roles of dietary bmOPN in infancy. The exposure of breastfed infants to human milk OPN (hmOPN) has been well-characterized and decreases markedly over the first 6 months of lactation. Dietary bmOPN is resistant to gastric and intestinal digestion, absorbed and cleared from circulation within 8–24 h, and represents a small portion (<5%) of total plasma OPN. Label studies on hmOPN suggest that after 3 h, intact or digested OPN is absorbed into carcass (62%), small intestine (23%), stomach (5%), and small intestinal perfusate (4%), with <2% each found in the cecum, liver, brain, heart, and spleen. Although the results are heterogenous with respect to bmOPN’s physiologic impact, no adverse impacts have been reported across growth, gastrointestinal, immune, or brain-related outcomes. Recombinant bovine and human forms demonstrate similar absorption in plasma as bmOPN, as well as effects on cognition and immunity. The panel recommended prioritization of trials measuring a comprehensive set of clinically relevant outcomes on immunity and cognition to confirm the safety of bmOPN over that of further research on its absorption, distribution, metabolism, and excretion. This review offers expert consensus on the adequacy of data available to assess the safety of bmOPN for use in infant formula, aiding evidence-based decisions on the formulation of infant formula.

Originalsprog	Engelsk
Artikelnummer	1404303
Tidsskrift	Frontiers in nutrition
Vol/bind	11
ISSN	2296-861X
DOI	https://doi.org/10.3389/fnut.2024.1404303
Status	Udgivet - 2024

Adgang til dokumentet

10.3389/fnut.2024.1404303

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Andre filer og links

Link to publication in Scopus

Citationsformater

Fleming, S. A., Reyes, S. M., Donovan, S. M., Hernell, O., Jiang, R., Lönnerdal, B., Neu, J., Steinman, L., Sørensen, E. S., West, C. E., Kleinman, R., & Wallingford, J. C. (2024). An expert panel on the adequacy of safety data and physiological roles of dietary bovine osteopontin in infancy. Frontiers in nutrition, 11, Artikel 1404303. https://doi.org/10.3389/fnut.2024.1404303

@article{ed5f088c216041d4903733e98f10ef5f,

title = "An expert panel on the adequacy of safety data and physiological roles of dietary bovine osteopontin in infancy",

abstract = "Human milk, due to its unique composition, is the optimal standard for infant nutrition. Osteopontin (OPN) is abundant in human milk but not bovine milk. The addition of bovine milk osteopontin (bmOPN) to formula may replicate OPN{\textquoteright}s concentration and function in human milk. To address safety concerns, we convened an expert panel to assess the adequacy of safety data and physiological roles of dietary bmOPN in infancy. The exposure of breastfed infants to human milk OPN (hmOPN) has been well-characterized and decreases markedly over the first 6 months of lactation. Dietary bmOPN is resistant to gastric and intestinal digestion, absorbed and cleared from circulation within 8–24 h, and represents a small portion (<5%) of total plasma OPN. Label studies on hmOPN suggest that after 3 h, intact or digested OPN is absorbed into carcass (62%), small intestine (23%), stomach (5%), and small intestinal perfusate (4%), with <2% each found in the cecum, liver, brain, heart, and spleen. Although the results are heterogenous with respect to bmOPN{\textquoteright}s physiologic impact, no adverse impacts have been reported across growth, gastrointestinal, immune, or brain-related outcomes. Recombinant bovine and human forms demonstrate similar absorption in plasma as bmOPN, as well as effects on cognition and immunity. The panel recommended prioritization of trials measuring a comprehensive set of clinically relevant outcomes on immunity and cognition to confirm the safety of bmOPN over that of further research on its absorption, distribution, metabolism, and excretion. This review offers expert consensus on the adequacy of data available to assess the safety of bmOPN for use in infant formula, aiding evidence-based decisions on the formulation of infant formula.",

keywords = "gastrointestinal, immunity, infant, milk, neurodevelopment, osteopontin, safety",

author = "Fleming, {Stephen A.} and Reyes, {Sarah M.} and Donovan, {Sharon M.} and Olle Hernell and Rulan Jiang and Bo L{\"o}nnerdal and Josef Neu and Lawrence Steinman and S{\o}rensen, {Esben S.} and West, {Christina E.} and Ronald Kleinman and Wallingford, {John C.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2024 Fleming, Reyes, Donovan, Hernell, Jiang, L{\"o}nnerdal, Neu, Steinman, S{\o}rensen, West, Kleinman and Wallingford.",

year = "2024",

doi = "10.3389/fnut.2024.1404303",

language = "English",

volume = "11",

journal = "Frontiers in nutrition",

issn = "2296-861X",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - An expert panel on the adequacy of safety data and physiological roles of dietary bovine osteopontin in infancy

AU - Fleming, Stephen A.

AU - Reyes, Sarah M.

AU - Donovan, Sharon M.

AU - Hernell, Olle

AU - Jiang, Rulan

AU - Lönnerdal, Bo

AU - Neu, Josef

AU - Steinman, Lawrence

AU - Sørensen, Esben S.

AU - West, Christina E.

AU - Kleinman, Ronald

AU - Wallingford, John C.

PY - 2024

Y1 - 2024

N2 - Human milk, due to its unique composition, is the optimal standard for infant nutrition. Osteopontin (OPN) is abundant in human milk but not bovine milk. The addition of bovine milk osteopontin (bmOPN) to formula may replicate OPN’s concentration and function in human milk. To address safety concerns, we convened an expert panel to assess the adequacy of safety data and physiological roles of dietary bmOPN in infancy. The exposure of breastfed infants to human milk OPN (hmOPN) has been well-characterized and decreases markedly over the first 6 months of lactation. Dietary bmOPN is resistant to gastric and intestinal digestion, absorbed and cleared from circulation within 8–24 h, and represents a small portion (<5%) of total plasma OPN. Label studies on hmOPN suggest that after 3 h, intact or digested OPN is absorbed into carcass (62%), small intestine (23%), stomach (5%), and small intestinal perfusate (4%), with <2% each found in the cecum, liver, brain, heart, and spleen. Although the results are heterogenous with respect to bmOPN’s physiologic impact, no adverse impacts have been reported across growth, gastrointestinal, immune, or brain-related outcomes. Recombinant bovine and human forms demonstrate similar absorption in plasma as bmOPN, as well as effects on cognition and immunity. The panel recommended prioritization of trials measuring a comprehensive set of clinically relevant outcomes on immunity and cognition to confirm the safety of bmOPN over that of further research on its absorption, distribution, metabolism, and excretion. This review offers expert consensus on the adequacy of data available to assess the safety of bmOPN for use in infant formula, aiding evidence-based decisions on the formulation of infant formula.

AB - Human milk, due to its unique composition, is the optimal standard for infant nutrition. Osteopontin (OPN) is abundant in human milk but not bovine milk. The addition of bovine milk osteopontin (bmOPN) to formula may replicate OPN’s concentration and function in human milk. To address safety concerns, we convened an expert panel to assess the adequacy of safety data and physiological roles of dietary bmOPN in infancy. The exposure of breastfed infants to human milk OPN (hmOPN) has been well-characterized and decreases markedly over the first 6 months of lactation. Dietary bmOPN is resistant to gastric and intestinal digestion, absorbed and cleared from circulation within 8–24 h, and represents a small portion (<5%) of total plasma OPN. Label studies on hmOPN suggest that after 3 h, intact or digested OPN is absorbed into carcass (62%), small intestine (23%), stomach (5%), and small intestinal perfusate (4%), with <2% each found in the cecum, liver, brain, heart, and spleen. Although the results are heterogenous with respect to bmOPN’s physiologic impact, no adverse impacts have been reported across growth, gastrointestinal, immune, or brain-related outcomes. Recombinant bovine and human forms demonstrate similar absorption in plasma as bmOPN, as well as effects on cognition and immunity. The panel recommended prioritization of trials measuring a comprehensive set of clinically relevant outcomes on immunity and cognition to confirm the safety of bmOPN over that of further research on its absorption, distribution, metabolism, and excretion. This review offers expert consensus on the adequacy of data available to assess the safety of bmOPN for use in infant formula, aiding evidence-based decisions on the formulation of infant formula.

KW - gastrointestinal

KW - immunity

KW - infant

KW - milk

KW - neurodevelopment

KW - osteopontin

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=85196853404&partnerID=8YFLogxK

U2 - 10.3389/fnut.2024.1404303

DO - 10.3389/fnut.2024.1404303

M3 - Review

C2 - 38919388

AN - SCOPUS:85196853404

SN - 2296-861X

VL - 11

JO - Frontiers in nutrition

JF - Frontiers in nutrition

M1 - 1404303

ER -

An expert panel on the adequacy of safety data and physiological roles of dietary bovine osteopontin in infancy

Abstract

Adgang til dokumentet

Biblioteksadgang?

Andre filer og links

Fingeraftryk

Citationsformater